Emerald Health Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing a new class of medicines to treat neurodegenerative, autoimmune and other diseases, has received a positive safety review following a pre-specified interim analysis by the Safety review committee (“SRC”) of its phase 2a study of EHP-101 for systemic sclerosis (“SSc”). EHP-101 is an oral formulation of VCE-004.8, a multitarget synthetic CBD derivative. The SRC has recommended that the trial continue without modification. EHP expects to report interim results from the study in early 2023.

The SRC is comprised of two physicians, one independent and the other the principal investigator in the trial. The SRC evaluated the blinded safety data from all patients enrolled in cohorts 1 and 2 at least up to …

Full story available on Benzinga.com